Cargando…
In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines
Intrinsic or added immune activating molecules are key for most vaccines to provide desired immunity profiles but may increase systemic reactogenicity. Regulatory agencies require rabbit pyrogen testing (RPT) for demonstration of vaccine reactogenicity. Recently, the monocyte activation test (MAT) g...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403550/ https://www.ncbi.nlm.nih.gov/pubmed/37542099 http://dx.doi.org/10.1038/s41598-023-39908-7 |
_version_ | 1785085092633247744 |
---|---|
author | Molenaar-de Backer, Marijke W. A. Doodeman, Paulien Rezai, Fereshte Verhagen, Lisa M. van der Ark, Arno Plagmeijer, Els M. Metz, Bernard van Vlies, Naomi Ophorst, Olga Raeven, René H. M. |
author_facet | Molenaar-de Backer, Marijke W. A. Doodeman, Paulien Rezai, Fereshte Verhagen, Lisa M. van der Ark, Arno Plagmeijer, Els M. Metz, Bernard van Vlies, Naomi Ophorst, Olga Raeven, René H. M. |
author_sort | Molenaar-de Backer, Marijke W. A. |
collection | PubMed |
description | Intrinsic or added immune activating molecules are key for most vaccines to provide desired immunity profiles but may increase systemic reactogenicity. Regulatory agencies require rabbit pyrogen testing (RPT) for demonstration of vaccine reactogenicity. Recently, the monocyte activation test (MAT) gained popularity as in vitro alternative, yet this assay was primarily designed to test pyrogen-free products. The aim was to adjust the MAT to enable testing of pyrogen containing vaccines in an early stage of development where no reference batch is yet available. The MAT and RPT were compared for assessing unknown safety profiles of pertussis outer membrane vesicle (OMV) vaccine candidates to those of Bexsero as surrogate reference vaccine. Pertussis OMVs with wild-type LPS predominantly activated TLR2 and TLR4 and were more reactogenic than Bexsero. However, this reactogenicity profile for pertussis OMVs could be equalized or drastically reduced compared to Bexsero or a whole-cell pertussis vaccine, respectively by dose changing, modifying the LPS, intranasal administration, or a combination of these. Importantly, except for LPS modified products, reactogenicity profiles obtained with the RPT and MAT were comparable. Overall, we demonstrated that this pertussis OMV vaccine candidate has an acceptable safety profile. Furthermore, the MAT proved its applicability to assess reactogenicity levels of pyrogen containing vaccines at multiple stages of vaccine development and could eventually replace rabbit pyrogen testing. |
format | Online Article Text |
id | pubmed-10403550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-104035502023-08-06 In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines Molenaar-de Backer, Marijke W. A. Doodeman, Paulien Rezai, Fereshte Verhagen, Lisa M. van der Ark, Arno Plagmeijer, Els M. Metz, Bernard van Vlies, Naomi Ophorst, Olga Raeven, René H. M. Sci Rep Article Intrinsic or added immune activating molecules are key for most vaccines to provide desired immunity profiles but may increase systemic reactogenicity. Regulatory agencies require rabbit pyrogen testing (RPT) for demonstration of vaccine reactogenicity. Recently, the monocyte activation test (MAT) gained popularity as in vitro alternative, yet this assay was primarily designed to test pyrogen-free products. The aim was to adjust the MAT to enable testing of pyrogen containing vaccines in an early stage of development where no reference batch is yet available. The MAT and RPT were compared for assessing unknown safety profiles of pertussis outer membrane vesicle (OMV) vaccine candidates to those of Bexsero as surrogate reference vaccine. Pertussis OMVs with wild-type LPS predominantly activated TLR2 and TLR4 and were more reactogenic than Bexsero. However, this reactogenicity profile for pertussis OMVs could be equalized or drastically reduced compared to Bexsero or a whole-cell pertussis vaccine, respectively by dose changing, modifying the LPS, intranasal administration, or a combination of these. Importantly, except for LPS modified products, reactogenicity profiles obtained with the RPT and MAT were comparable. Overall, we demonstrated that this pertussis OMV vaccine candidate has an acceptable safety profile. Furthermore, the MAT proved its applicability to assess reactogenicity levels of pyrogen containing vaccines at multiple stages of vaccine development and could eventually replace rabbit pyrogen testing. Nature Publishing Group UK 2023-08-04 /pmc/articles/PMC10403550/ /pubmed/37542099 http://dx.doi.org/10.1038/s41598-023-39908-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Molenaar-de Backer, Marijke W. A. Doodeman, Paulien Rezai, Fereshte Verhagen, Lisa M. van der Ark, Arno Plagmeijer, Els M. Metz, Bernard van Vlies, Naomi Ophorst, Olga Raeven, René H. M. In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines |
title | In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines |
title_full | In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines |
title_fullStr | In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines |
title_full_unstemmed | In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines |
title_short | In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines |
title_sort | in vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403550/ https://www.ncbi.nlm.nih.gov/pubmed/37542099 http://dx.doi.org/10.1038/s41598-023-39908-7 |
work_keys_str_mv | AT molenaardebackermarijkewa invitroalternativeforreactogenicityassessmentofoutermembranevesiclebasedvaccines AT doodemanpaulien invitroalternativeforreactogenicityassessmentofoutermembranevesiclebasedvaccines AT rezaifereshte invitroalternativeforreactogenicityassessmentofoutermembranevesiclebasedvaccines AT verhagenlisam invitroalternativeforreactogenicityassessmentofoutermembranevesiclebasedvaccines AT vanderarkarno invitroalternativeforreactogenicityassessmentofoutermembranevesiclebasedvaccines AT plagmeijerelsm invitroalternativeforreactogenicityassessmentofoutermembranevesiclebasedvaccines AT metzbernard invitroalternativeforreactogenicityassessmentofoutermembranevesiclebasedvaccines AT vanvliesnaomi invitroalternativeforreactogenicityassessmentofoutermembranevesiclebasedvaccines AT ophorstolga invitroalternativeforreactogenicityassessmentofoutermembranevesiclebasedvaccines AT raevenrenehm invitroalternativeforreactogenicityassessmentofoutermembranevesiclebasedvaccines |